TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31536837
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of placebo (10 mL of 1.5% glycine) in the same form inside every 1000 mL of the distention medium
Study: 31557812
Drug: Polar M400
Normalized name: Polar Freeze
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polar M400 use and twice‐weekly social cognitive theory‐ and self‐determination theory‐based Facebook‐delivered health education intervention
Study: 29101095
Drug: Smartphone CBT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smartphone CBT app (Kokoro-app) in addition to medication change
Study: 21991727
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg tramadol (group T, n = 35)
Study: 21991727
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg lidocaine 2% (group L, n = 35)
Study: 11322206
Drug: 10 MU
Normalized name: saliva substitute comb no.10 MUCOUS MEM POWDER IN PACKET (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 MU IFN daily
Study: 11322206
Drug: 5 MU
Normalized name: MULTISTIX 5 MULTIPLE TEST STRIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 MU twice-daily
Study: 8646870
Drug: Betamethasone valerate
Normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Betamethasone valerate cream, 0.1%
Study: 2258448
Drug: Fenfluramine 40‐120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine 40‐120 mg/day
Study: 498825
Drug: Terbutaline 2.5
Normalized name: terbutaline 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 2.5 mg
Study: 7416558
Drug: Theophylline 130
Normalized name: theophylline 130 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 130 mg
Study: 7416558
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Theophylline 130 mg and Terbutaline 2.5 mg
Study: 28382660
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (medical treatment and routine care only, without intervention)
Study: 18614727
Drug: Bolus tube
Normalized name: Sus scrofa fallopian tube preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus tube feeding (6.93 ± 0.38 MJ/d of 4.18 kJ/mL multinutrient feed)
Study: 12108334
Drug: Intravenous interleukin-2
Normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous interleukin-2
Study: 12108334
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of interleukin-2 and interferon
Study: 8646822
Drug: Erythromycin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (400 mg orally three times a day for 10 days)
Study: 1475039
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg pyritinol dihydrochloride-monohydrate, 3 times daily for 12 weeks
Study: 6706234
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (various modalities)
Study: 6706234
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further treatment after primary surgery
Study: 25427553
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment without reduction of the fracture
Study: 18763027
Drug: acitretin 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: acitretin 0.4 mg/kg per day
Study: 17367446
Drug: Parenteral testosterone
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Parenteral testosterone (Sustanon 250 intramuscular injection)
Study: 17367446
Drug: Letrozole 2.5
Normalized name: letrozole 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole 2.5 mg orally daily
Study: 8229622
Drug: Control oral
Normalized name: Dayquil Mucus Control Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control oral hygiene methods
Study: 26463007
Drug: L-epinephrine plus
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-epinephrine plus dexamethasone
Study: 14568987
Drug: High-dose etoposide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose etoposide, ifosfamide, and cisplatin (VIP) chemotherapy plus autologous stem cell support, administered in one cycle followed by three to four sequential cycles every 3 weeks.
Study: 14568987
Drug: High-dose VIP
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose VIP chemotherapy with stem cell support.
Study: 14568987
Drug: Dose level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose level 6 of high-dose VIP (cisplatin 100 mg/m2, etoposide 1500 mg/m2, ifosfamide 10 g/m2) recommended for further investigation.
Study: 1455371
Drug: Hemosorption weekly
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hemosorption weekly for 3 weeks, followed by cyclophosphamide 1000 mg IV after the second procedure, then methotrexate 7.5 mg weekly.
Study: 1455371
Drug: Methotrexate 7.5
Normalized name: methotrexate 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methotrexate 7.5 mg weekly.
Study: 1455371
Drug: Cyclophosphamide 200
Normalized name: cyclophosphamide 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 200 mg IV twice a week for 6 times, then 200 mg weekly orally until a total dose of 2 g.
Study: 1455371
Drug: Azathioprine 100
Normalized name: azathioprine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azathioprine 100 mg daily.
Study: 3334188
Drug: Ranitidine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine at 300 mg daily for the control of symptoms of non-ulcer dyspepsia
Study: 29746903
Drug: famciclovir 500mg
Normalized name: FAMCICLOVIR 500MG TAB
DrugBank: Famciclovir (DB00426)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: famciclovir 500mg (one tablet) three times daily for 7 days
Study: 29746903
Drug: acyclovir 800mg
Normalized name: ACYCLOVIR 800MG TAB
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: acyclovir 800mg (two capsules) five times daily for 7 days
Study: 27354043
Drug: Long-acting nifedipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting nifedipine (10-60 mg/day)
Study: 24355438
Drug: Protein pulse
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein pulse feeding (PD), 72% of dietary protein consumed in one meal at noon, averaging 1.31 g/kg body weight daily
Study: 24355438
Drug: Protein spread
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protein spread feeding (SD), dietary protein spread over four daily meals
Study: 21502597
Drug: Huperzine A
Normalized name: Huperzine A
DrugBank: Huperzine A (DB04864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huperzine A 200 μg BID
Study: 21502597
Drug: Huperzine A
Normalized name: Huperzine A
DrugBank: Huperzine A (DB04864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Huperzine A 400 μg BID
Study: 16766774
Drug: Special nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Special nutritional supplement providing 90 mg isoflavones, 800 mg calcium, 400 IU vitamin D, 60 ug vitamin K and 31 g proteins per day.
Study: 16766774
Drug: Usual nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual nutritional supplement provided by the Chilean Ministry of Health.
Study: 11115724
Drug: Rhesus rotavirus-based
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhesus rotavirus-based quadrivalent vaccine
Study: 9543218
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg of micronised flavonoid fraction for 2 months
Study: 19734790
Drug: gabapentin 1200
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gabapentin 1200 mg + dexamethasone 8 mg + ketamine (0.15 mg kg(‐1)) + paracetamol 1 g + ketorolac 15 mg
Study: 19734790
Drug: placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo + paracetamol 1 g + ketorolac 15 mg
Study: 18364384
Drug: Diet and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet and exercise (treatment group; n = 17)
Study: 18364384
Drug: No therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: No therapy (control group; n = 10)
Study: 15452357
Drug: Cream adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream adjusted to pH 4.0
Study: 15452357
Drug: Cream adjusted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream adjusted to pH 7.5
Study: 12417880
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (FP) 150 microg twice daily, n = 20
Study: 7532559
Drug: Methylene blue
Normalized name: Methylene Blue
DrugBank: Methylene blue (DB09241)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylene blue (2 mg/kg)
Study: 6123021
Drug: Synthetic methionyl
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic methionyl human growth hormone
Study: 6123021
Drug: Pituitary human
Normalized name: posterior pituitary hormones
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pituitary human growth hormone
Study: 19067286
Drug: IV ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV ibuprofen (10 mg/kg, 5 mg/kg, and 5 mg/kg over 3 days)
Study: 16112120
Drug: Vegetable lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable lipid intake >or=34.4 g/day
Study: 16112120
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E intake >or=7.726 mg/day
Study: 11775393
Drug: Budesonide inhalation
Normalized name: Budesonide Inhalation Powder
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide inhalation suspension (BIS; Pulmicort Respules)
Study: 10518847
Drug: Conventional asthma
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional asthma therapy (CAT)
Study: 31759183
Drug: MGO Manuka
Normalized name: manuka oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGO Manuka Honey microemulsion eye cream applied to one eye overnight for 3 months
Study: 31759183
Drug: MGO Manuka
Normalized name: manuka oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: MGO Manuka Honey microemulsion eye cream
Study: 25740268
Drug: Pradigastat 40
Normalized name: Pradigastat
DrugBank: Pradigastat (DB12866)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pradigastat 40 mg with a single dose of Levora‐28®
Study: 24122191
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment (HBOT) administered within 24 h to 48 h of burn injury
Study: 18984264
Drug: Oral montelukast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral montelukast for 8 weeks in addition to oral prednisolone for 14 days and budenoside nasal spray for 8 weeks
Study: 18984264
Drug: Oral prednisolone
Normalized name: prednisolone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prednisolone for 14 days and budenoside nasal spray for 8 weeks (Control)
Study: 15465071
Drug: GAD patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD patients (preanxiolytic treatment)
Study: 15465071
Drug: Anxiolytic-treated GAD
Normalized name: trimethylsilyl treated diimethiconol-trimethylsiloxysilicate crosspolymer (45-55 WW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anxiolytic-treated GAD patients
Study: 15465071
Drug: GAD patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD patients after treatment
Study: 11465435
Drug: Autologous blood
Normalized name: Banked autologous blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous blood transfusion with intravenous injection of erythropoietin 600 lU/kg after each blood predonation
Study: 9509446
Drug: Haemodialysis for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemodialysis for 3 hours started after contrast medium administration
Study: 8044451
Drug: Tiagabine (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiagabine (32 mg during open phase, 24 mg during double-blind phase)
Study: 3056807
Drug: Biosynthetic human
Normalized name: Proinsulin biosynthetic human
DrugBank: Proinsulin human (DB17875)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosynthetic human insulin (0.025, 0.05, 0.1 units/kg)
Study: 30328970
Drug: 1,000 mg
Normalized name: bran 1,000 mg ORAL WAFER
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg mangosteen pericarp per day for 24 weeks
Study: 17040484
Drug: Chlorhexidine (CHX)
Normalized name: chlorhexidine gluconate Topical Solution [CHX Plus]
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chlorhexidine (CHX) chewing gum, 5 mg, 2 pieces, twice a day for 3 months
Study: 9073005
Drug: Deep inhalation
Normalized name: Deep Sea Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep inhalation
Study: 9073005
Drug: Forceful and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forceful and deep inhalation
Study: 18412958
Drug: Daily acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily acid regurgitation
Study: 16215331
Drug: Controlled-release oxycodone
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled-release oxycodone (OxyContin)
Study: 11940291
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose recombinant tissue-type plasminogen activator (rt-PA) thrombolysis
Study: 7650092
Drug: MPH (Methylphenidate);
Approvals — FDA: no, EMA: no, PMDA: no
Description: MPH (Methylphenidate); specific dosage and duration not mentioned
Study: 2719748
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms of muroctasin (L group)
Study: 1174902
Drug: Aminocaproic acid
Normalized name: Aminocaproic Acid
DrugBank: Aminocaproic acid (DB00513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminocaproic acid 3 g taken six-hourly during menstruation
Study: 31618495
Drug: Oral taurine
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral taurine for 12 weeks
Study: 16527639
Drug: Removable appliance
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Removable appliance with palatal crib combined with high-pull chincup therapy
Study: 6851273
Drug: Metoprolol, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol, 200 mg daily
Study: 21128060
Drug: S-1 monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 monotherapy (40 mg/m², orally twice daily, days 1-28, every 6 weeks)
Study: 17951625
Drug: SFC (salmeterol
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFC (salmeterol 50 microg/fluticasone 500 microg, twice daily)
Study: 2801590
Drug: Liquid cow-milk-based
Normalized name: Cow milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid cow-milk-based formula containing 1.3 mumol Cu/L (n = 16)
Study: 2801590
Drug: Liquid cow-milk-based
Normalized name: Cow milk
DrugBank: Cow milk (DB10543)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liquid cow-milk-based formula supplemented with 7.8 mumol Cu/L as Cu sulfate (n = 16)
Study: 30125376
Drug: 250 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg/kg acetylcysteine over 12 hours
Study: 30125376
Drug: 300 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/kg acetylcysteine over 20 hours
Study: 28845931
Drug: Adjuvant antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant antioxidant therapy with SpermActin-forte (SA)
Study: 28845931
Drug: Adjuvant antioxidant
Normalized name: antioxidant 119
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant antioxidant therapy with SpermActin-forte (SA) and vitamin complex (VC)
Study: 25117173
Drug: Daclatasvir 60
Normalized name: daclatasvir 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir 60 mg once daily and asunaprevir 200 mg twice daily (combination dosing for 14 days)
Study: 25117173
Drug: Daclatasvir and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir and asunaprevir administered together or alone in HCV patients
Study: 16119487
Drug: S-ketamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine (1 mg/kg) with priming (0.04 mg/kg of rocuronium)
Study: 16119487
Drug: S-ketamine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-ketamine (1 mg/kg) without priming
Study: 16119487
Drug: Thiopentone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (4 mg/kg) with priming (0.04 mg/kg of rocuronium)
Study: 16119487
Drug: Thiopentone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (4 mg/kg) without priming
Study: 16119487
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (sham priming with saline) with S-ketamine (1 mg/kg)
Study: 16119487
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (sham priming with saline) with thiopentone (4 mg/kg)
Study: 12296586
Drug: Daily treatment
Normalized name: BENZOYL PEROXIDE 2.5 g in 100 g TOPICAL GEL [Acne defense Daily Treatment Serum Merle Norman]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily treatment (full-mouth daily scaling and root planing for 4 consecutive days)
Study: 12296586
Drug: Weekly treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly treatment (once a week for 4 weeks)
Study: 3092656
Drug: Sucralfate 1
Normalized name: sucralfate 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 1 g four times daily
Study: 6110957
Drug: Nicotinic acid
Normalized name: Nicotinic acid
DrugBank: Niacin (DB00627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotinic acid (25 mg)
Study: 24074879
Drug: NPLD (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPLD (60 mg/mq iv) plus cyclophosphamide (600 mg/mq iv) every 3 weeks for 4 cycles followed by docetaxel (35 mg/mq iv) plus trastuzumab (4 mg/mq loading dose iv, then 2 mg/mq iv) weekly for 16 weeks
Study: 15452611
Drug: Epithalamin (peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epithalamin (peptide preparation from the pineal gland)
Study: 11552904
Drug: Rabeprazole 10
Normalized name: RABEprazole 10 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 10 mg b.d.
Study: 11552904
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg o.m.
Study: 27063478
Drug: Ambrisentan (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambrisentan (10 mg per day)
Study: 24943851
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment Simultaneously Targeting Obesity and Pain (STOP)
Study: 22627057
Drug: Loteprednol etabonate
Normalized name: Loteprednol Etabonate
DrugBank: Loteprednol etabonate (DB14596)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loteprednol etabonate suspension 0.2% administered QID
Study: 22627057
Drug: Olopatadine solution
Normalized name: olopatadine Ophthalmic Solution
DrugBank: Olopatadine (DB00768)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olopatadine solution 0.1% administered BID
Study: 15869587
Drug: Second generation
Normalized name: Second generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second generation oral contraceptives
Study: 15869587
Drug: Third generation
Normalized name: Third generation cephalosporin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third generation oral contraceptives
Study: 12534456
Drug: Montelukast 10
Normalized name: montelukast 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast 10 mg day-1 for 3 weeks
Study: 8570773
Drug: Biperiden (Akineton)
Normalized name: biperiden hydrochloride Oral Tablet [Akineton]
DrugBank: Biperiden (DB00810)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biperiden (Akineton) 12 mg/day for 4 weeks
Study: 8570773
Drug: Glycopyrrolate (Robinul)
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycopyrrolate (Robinul) 1 mg/day for 4 weeks
Study: 8570773
Drug: Biperiden (Akineton)
Normalized name: biperiden hydrochloride Oral Tablet [Akineton]
DrugBank: Biperiden (DB00810)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biperiden (Akineton) 12 mg/day for 1 week
Study: 1700927
Drug: Combined modality
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined modality therapy (chemotherapy followed by radiation therapy)
Study: 535132
Drug: Divided dose
Normalized name: Aluminum Zirconium Trichlorohydrex Gly 20 g in 100 g TOPICAL STICK [Dividends]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Divided dose regimen of 25 mg methotrexate taken at 2-hour intervals (total 100 mg)
Study: 535132
Drug: Single 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 100 mg oral dose of methotrexate
Study: 23593417
Drug: rhGH 3
Normalized name: rhGH
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH 3 mg daily
Study: 23593417
Drug: Combination rhGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination rhGH + rosiglitazone
Study: 20095368
Drug: D-cycloserine 100
Normalized name: D-(+)-cycloserine
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-cycloserine 100 mg
Study: 14985219
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg FeSO(4)
Study: 10101526
Drug: Azelastine nasal
Normalized name: azelastine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelastine nasal spray (0.56 mg intranasally daily for two weeks)
Study: 7828351
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone therapy for 4 months
Study: 7828351
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 4 months
Study: 30415813
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg/d and Solifenacin 10 mg/d
Study: 30415813
Drug: Dutasteride 0.5
Normalized name: dutasteride 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride 0.5 mg/d and Solifenacin 20 mg/d